Dyax Extends Collaboration With ImClone

Dyax has extended its collaboration with ImClone Systems for the discovery of therapeutic antibodies.

Under the terms of this agreement, ImClone will continue to have access to Dyax’s proprietary phage display technology for an additional four years.

ImClone has advanced into Phase II clinical trials three fully human monoclonal antibodies against epidermal growth factor receptor, insulin-like growth factor 1 and kinase insert domain-containing receptor identified using Dyax’s proprietary technology.

Under the agreement, Dyax will continue to receive annual license fees from ImClone, as well as clinical milestone payments and royalties on net sales that may result from ImClone’s development and commercialization of antibodies from Dyax’s libraries, Dyax said.